Navigation Links
Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Date:12/10/2012

9–158) days and 64 (30–125) days, respectively.1

Secondary endpoints included event-free survival (EFS), overall survival (OS) and safety.  EFS was measured from the date of randomization to the date of disease progression (treatment failure), relapse or death from any cause, whichever occurred first.  In patients treated with the combination of volasertib plus LDAC, the median EFS was approximately 5.6 months (170 days) compared with approximately 2.3 months (69 days) in patients treated with LDAC alone (hazard ratio: 0.56; 95% CI: 0.34, 0.93; p=0.0237).  Follow-up for overall survival was ongoing at the time of this analysis.1   

"The preliminary results from this trial provide insight into the potential of volasertib combined with LDAC in patients with AML not eligible for intensive induction chemotherapy," said Berthold Greifenberg, M.D., vice president, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc.  "Based on the results observed in this difficult-to-treat patient population, we are expanding our volasertib hematology clinical program to further explore this investigational compound." 

In the volasertib plus LDAC treatment arm (n=42), grade 5 non-hematologic adverse events (AEs) were infections (5%), febrile neutropenia (5%) and respiratory/thoracic/mediastinal events (7%).  Grade 3/4 non-hematologic AEs were gastrointestinal events (19/2%), general events (14/2%), infections (38/5%), febrile neutropenia (38/7%), metabolism/nutrition events (10/5%) and respiratory/thoracic/mediastinal events (14/2%).  In the LDAC monotherapy arm (n=45), grade 5 non-hematologic AEs were infections (9%), and grade 3/4 non-hematologic AEs were gastrointestinal events (7/0%), general events (16/2%), infections (7/7%), febrile neutropenia (4/9%), metabolism/nutrition events (7/0%) and respiratory/thoracic/mediastinal events (11/2%
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Announces Equine Research Awards
2. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
3. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
4. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013  This year alone, The ... 300 research projects with one goal in mind: Discovering ... "Team In Training" (TNT), a flagship LLS fundraising campaign ... program, is marking its landmark 25 th anniversary. ... $875 million in research to discover and deliver breakthrough ...
(Date:6/19/2013)... YORK , June 19, 2013 ... brand new infographic summary of the results from ... a third of all respondents stated that CROs would be ... 50% of respondents will be running 6 or more clinical ... with the Clinical Trial Supply USA ...
(Date:6/18/2013)... YORK , June 18, 2013  Intercept Pharmaceuticals, ... biopharmaceutical company focused on the development and commercialization of ... today announced the pricing of an underwritten public offering ... public offering price of $33.01 per share.  In addition, ... purchase up to an additional 259,500 shares of common ...
Breaking Medicine Technology:Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... PLAINS, N.Y., AUG. 2 Two major studies,published today ... doctors,better identify pregnant women at risk for preterm delivery ... Foundation said today. In one large multi-center trial ... (most of whom had no prior history of preterm ...
... - Access to Large Population of Glioblastoma Patients Expected ... Phase ll Study of Promising New Approach -, ... PPHM ), a clinical stage biopharmaceutical,company developing targeted monoclonal ... infection, today announced that the first,patient has been administered ...
Cached Medicine Technology:Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 3Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 4
(Date:6/19/2013)... 2013) In early April, senior leaders from medical, ... Connecticut, to discuss one question: how can first responders ... , The preliminary results of this discussion are now ... The Hartford Consensus ," a concept paper published in ... of Trauma and Acute Care Surgery , official ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Effective Environmental Services ... of new websites. These online links are devoted to a ... Tank cleaner, Organic Odor Control Mold Magician and others. , ... fish and animals in the water as well as living ... sludge buildup that can accumulate at the bottom of a ...
(Date:6/19/2013)... Ky. (PRWEB) June 19, 2013 Dental ... during sedation because from minor to moderate sedation, a ... Oregon Board of Dentistry is the latest to update ... moderate and deep sedation in an effort to increase ... the Oregon Dental Practice Act goes into effect July ...
(Date:6/19/2013)... Brightree LLC , the leading provider of cloud-based ... care industry, has been ranked for the first time - ... (HCI 100) list. This prestigious list features the top ... revenue during the last fiscal year. Since 2005, Brightree’s revenue ... the company has built its organization to more than 500 ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 At a Travel ... positive changes and growth that has occurred over the last ... club. , Shuman said, "Travel Services has added vendors, lowered ... beyond belief. Membership is up, even in the tough ... the demands of members." , Having been in the Travel ...
Breaking Medicine News(10 mins):Health News:Hartford consensus aims to improve survival after mass shootings 2Health News:Effective Environmental Services Launch New Websites to Serve Customers 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2
... 8, 2011 - The Sea Grant programs of Connecticut ... grants valued at $1,130,832 to six projects that will look ... health of Long Island Sound, a water body designated by ... , Research results from five two-year projects and a one-year ...
... NC A UNC study released this week in the ... of squamous cell carcinoma of the oral tongue in young ... decades. A team of researchers from UNC Lineberger ... Surveillance, Epidemiology and End Results (SEER) database and found that, ...
... News) -- The percentage of personal bankruptcies caused by ... since Massachusetts began requiring people to buy health insurance ... challenges the Obama administration,s claim that medical bankruptcies will ... is largely patterned after the Massachusetts law, according to ...
... 2011 issue of the journal Heath Affairs ... implemented and tested by researchers and clinicians from Indiana ... Geriatric Resources for Assessment and Care of Elders (GRACE) ... lower income, older adults. GRACE is now in use ...
... physician-scientists at University Hospitals (UH) Case Medical Center are ... an early stage, aggressive type of breast cancer. ... of Breast Cancer Research at UH Case Medical Center,s ... breast cancer. Patients with this form of breast ...
... This release is available in Spanish and ... found to be 2.3-fold higher among Muslim adolescents than among ... the former group. Finally, as a general conclusion, an average ... disorder, and 15% suffers body dissatisfaction. These were the conclusions ...
Cached Medicine News:Health News:Sea grant awards more than $1.1 million for research under EPA's Long Island Sound study 2Health News:Sea grant awards more than $1.1 million for research under EPA's Long Island Sound study 3Health News:UNC study finds oral tongue cancer increasing in young, white females 2Health News:Mass. Health Reform Hasn't Halted Medical Bankruptcies 2Health News:Aging with grace: In-home assessments lead to better care, lower health costs 2Health News:Aging with grace: In-home assessments lead to better care, lower health costs 3Health News:Novel clinical trial aims to reduce recurrence of aggressive breast cancer 2Health News:Eating disorders and body dissatisfaction is double in Muslim teenagers than in Christian 2
... Steerability - Use the Attain Prevail's ... catheters and guide wires, to obtain the ... Inject contrast media for improved visualization of ... needed with tip deflection. Telescoping - ...
Attain™ Left-heart Lead Options to Fit Your Patient's Anatomy. Navigate moderately to greatly angled veins with high tortuosity....
... Mosaic, the third generation tissue valve from ... tissue valve available. The Mosaic valve builds ... and is an excellent choice for patients ... with a tissue valve. For more than ...
... Mitral bioprosthesis is a portrait ... based on 25 years of ... makes it an excellent choice ... replacement--particularly elderly patients and those ...
Medicine Products: